Shotsy - GLP-1 Tracker
US$ 25.41
obesity drug news today glp-1 october 2025 Poll: 1 in 8 Adults Say They Are Currently Taking a for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford GLP-1 trends 2025: real-world data,
Description
2024 Sep;63(9):1128-1130
Beyond their metabolic benefits, GLP-1RAs demonstrate immunomodulatory effects, including attenuation of systemic inflammation and modulation of immune cell activity, raising the possibility of relevance to autoimmune conditions such as AITD [9]
Taken together, these findings demonstrate that gut microbiota and their metabolites exert dual and context-dependent effects on GLP-1 secretion and signaling
Axelsen K
ELIXA: Evaluation of Lixisenatide in Acute Coronary Syndrome
[DOI] [PMC free article] [PubMed] [Google Scholar] 54.McClean P
